Zika virus: latest news - GoINPHARMA
Thursday, 18 October 2018 - 0:27

Zika virus

Takeda announces clinical trial for anti-Zika vaccine

Japan-based Takeda has announced a Phase I clinical trial for its anti-Zika (TAK-426) vaccine. The trial will have a minimum duration of 15 months and will be partly funded by the US Department of Health and Human Services, the Office…

Zika virus: positive results for Inovio’s vaccine published in NEJM

Inovio Pharmaceuticals has announced positive efficacy, safety and immune response results from its vaccine against the Zika virus. The data have emerged from a Phase I multi-center clinical trial, designed to assess Inovio’s GLS-5700 vaccine. The drug has induced high…

FDA approves test to detect Zika virus in blood donations

FDA has approved the cobas Zika test, by Roche Molecular System, in order to detect the Zika virus in plasma obtained from volunteer donors of whole blood and blood components. The test detects the virus in blood donations, it is…

Zika virus: state of the art

Zika virus first appeared around 1947 in Uganda, however the first cases of infections affecting humans were reported only in 1952. Between 1969 and 1973 the virus spread to Asia and, at the beginning of the 21st Century, reached Indonesia…

Sanofi Pasteur, Fiocruz and WRAIR to collaborate against Zika

Sanofi and Sanofi Pasteur announced today they have entered into a collaboration agreement with Oswaldo Cruz Foundation – by means of its institute known as Bio-Manguinhos/Fiocruz – and the Walter Reed Army Institute of Research (WRAIR), to develop a Zika…

iBData, Takeda’s new program to manage IBD

Takeda has stated that it is partnering with Vanderbilt University and Texas Digestive Disease Consultants (TDDC) in order to develop a digital program to help patients and physicians manage IBD (inflammatory bowel disease). The pilot program, iBData, which will initially…

Takeda begins extensive trial for new vaccine against Dengue

Takeda, the major Japanese pharma group, has started an important three-year clinical trial for the vaccine against dengue, including vaccination of 20,000 children in Asia and Latin America. The new vaccine TAK-003, developed by Takeda, will provide an alternative to…